

19 December 2006

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

Consultation on a provisional agreement with GlaxoSmithKline for the listing of sumatriptan (Imigran) on the Pharmaceutical Schedule

PHARMAC and GlaxoSmithKline NZ Limited have entered into a provisional agreement to amend the terms of listing of sumatriptan (Imigran) in Section B of the Pharmaceutical Schedule.

Key aspects of this proposal are as follows:

- The price and subsidy for sumatriptan (Imigran) tablets in Section B of the Pharmaceutical Schedule would decrease from 1 April 2007 as follows (ex-manufacturer, excluding GST):

Pharmaceutical	Brand	Form	Strength	Pack Size	Current price & subsidy	New price & subsidy
Sumatriptan	Imigran	Tablet	50 mg	4	\$34.00	\$22.00
Sumatriptan	Imigran	Tablet	100 mg	2	\$32.00	\$22.00

- Imigran tablets would remain fully subsidised from 1 April 2007, and would not be reference priced to Arrow-Sumatriptan (as notified on 17 November 2006).
- Imigran injection (sumatriptan 12 mg per ml, 0.5 ml) would remain listed in Section B of the Pharmaceutical Schedule fully subsidised at a price and subsidy of \$80 per 2 injections (ex-manufacturer, excluding GST). Imigran injection would continue to be subject to the "Hospital Pharmacy-Specialist" restriction that currently applies to the prescribing and dispensing of Imigran injection.
- Imigran tablets and injection would be subject to a confidential rebate, the effect of which would be to reduce the effective cost of Imigran 50 mg and 100 mg tablets to be in line with the price of generic sumatriptan tablets (to be listed on 1 April 2007).
- Imigran would have protection from delisting and subsidy reduction until 1 January 2010.

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by **5:00 pm, 17 January 2007**. All comments submitted by this date will be considered.

Yours sincerely



Geraldine MacGibbon
Therapeutic Group Manager

P5-5-1 #106108

Investing in Health